G1 Therapeutics Provides First Quarter 2023 Financial Result

- Drove 18% Quarterly Net Revenue Growth of COSELA® Over the Fourth Quarter of 2022; Grew Quarterly Vial Volume by 21% Over Prior Quarter - - Provided Updated Timing for Interim Overall Survival... | May 3, 2023

Related Keywords

United States , China , American , Jack Bailey , Johnw Umstead , Wedbush Pacgrow , Sacituzumab Govitecan Hziy , Raymond James , Nasdaq , Investor Relations Corporate Communications , Exchange Commission , European Society For Medical Oncology , American Society Of Clinical Oncology , Therapeutics Inc , Research Triangle Park , Needham Company , Drug Administration On , Quarterly Net Revenue Growth , Fourth Quarter , Grew Quarterly Vial Volume , Over Prior Quarter , Updated Timing , Interim Overall Survival , Pivotal Phase , Metastatic Triple Negative Breast Cancer , Analysis Now Expected , First Quarter , Antibody Drug Conjugate , Additional Results , Balance Sheet Through Monetization , Future Royalties , Providing Additional Near Term Capital , Host Webcast , Conference Call , Chief Executive Officer , Volume Growth Over , Cash Equivalents , Marketable Securities , Simcere Milestones , Greater China , Initial Results , Snow Expected , Upcoming Poster Presentation , Trilaciclib Phase , European Society , Medical Oncology , Breast Cancer , European Summer Time , Action Trial , American Society , Clinical Oncology , Initial Results Including , Primary Endpoint , Progression Free Survival , Cancer Trial , Are Anticipated Midyear , Drug Administration , Private Securities Litigation Reform Act , Investor Relations , Balance Sheet Data , Months Ended March , G1 Therapeutics , Nc Stock Exchange , News , Information , Press Release , Grove , Uarterly , Pet , Revenue , Growth , F , Dover , The , Fourth , Quarter , Crew , Trial , Volume , Y , Rior , Rovided , Pdated , Timing , Or , Interim , Verall Gthx Us3621lq1099 ,